Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study
- 237 Downloads
Endometrial cancer risk is increased by estrogens unopposed by progesterone. In premenopausal women, androgen excess is often associated with progesterone insufficiency, suggesting that premenopausal androgen concentrations may be associated with risk. In a case–control study nested within three cohorts, we assessed the relationship between premenopausal androgens and risk of endometrial cancer (161 cases and 303 controls matched on age and date of blood donation). Testosterone, DHEAS, androstenedione, and SHBG were measured in serum or plasma. Free testosterone was calculated from testosterone and SHBG. We observed trends of increasing risk across tertiles of testosterone (ORT3-T1 = 1.59, 95 % CI = 0.96, 2.64, p = 0.08) and free testosterone (ORT3-T1 = 1.76, 95 % CI = 1.01, 3.07, p = 0.047), which were not statistically significant after adjustment for body mass index (BMI). There was no association for DHEAS, androstenedione, or SHBG. There were significant interactions by age at diagnosis (<55 years, n = 51 cases; ≥55 years, n = 110 cases). Among women who were ≥55 years of age (predominantly postmenopausal) at diagnosis, the BMI-adjusted OR was 2.08 (95 % CI = 1.25, 3.44, p = 0.005) for a doubling in testosterone and 1.55 (95 % CI = 1.04, 2.31, p = 0.049) for a doubling in free testosterone. There was no association among women aged <55 years at diagnosis, consistent with the only other prospective study to date. If pre- and post-menopausal concentrations of androgens are correlated, our observation of an association of premenopausal androgens with risk among women aged ≥55 years at diagnosis could be due to the effect on the endometrium of postmenopausal androgen-derived estrogens in the absence of progesterone, which is no longer secreted.
KeywordsTestosterone Androgen Endometrial Cancer Blood Donation Androstenedione
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This work was supported by the National Cancer Institute (R01 CA081212, R01 CA098661, P30 CA016087 and UM1 CA182934) and the National Institute of Environmental Health Sciences (Center grant ES000260).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17(4):921–929. doi: 10.1158/1055-9965.EPI-07-2686 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC (2013) Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids 78(1):96–101. doi: 10.1016/j.steroids.2012.10.010 CrossRefPubMedGoogle Scholar
- 11.Rinaldi S, Dechaud H, Biessy C, Morin-Raverot V, Toniolo P, Zeleniuch-Jacquotte A, Akhmedkhanov A et al (2001) Reliability and validity of commercially available, direct radioimmunoassays for measurement of blood androgens and estrogens in postmenopausal women. Cancer Epidemiol Biomarkers Prev 10(7):757–765PubMedGoogle Scholar
- 12.Rinaldi S, Plummer M, Biessy C, Castellsague X, Overvad K, Kruger Kjaer S, Tjonneland A et al (2011) Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomarkers Prev 20(12):2532–2540. doi: 10.1158/1055-9965.EPI-11-0753 CrossRefPubMedGoogle Scholar
- 13.Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjonneland A, Olsen A et al (2014) Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—results from the EPIC cohort. Int J Cancer 134(8):1947–1957. doi: 10.1002/ijc.28528 CrossRefPubMedGoogle Scholar
- 14.Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, Shore RE, Riboli E, Toniolo P, Kaaks R (2002) Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1065–1071PubMedGoogle Scholar
- 15.Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC et al (2005) Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 111(10):1242–1249. doi: 10.1161/01.CIR.0000157697.54255.CE CrossRefPubMedGoogle Scholar
- 19.Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84(11):4006–4011. doi: 10.1210/jcem.84.11.6148 CrossRefPubMedGoogle Scholar
- 24.Revised (2003) consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. 2004. Fertil Steril 81(1):19–25Google Scholar
- 25.Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456–488. doi: 10.1016/j.fertnstert.2008.06.035 CrossRefPubMedGoogle Scholar
- 29.Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, Owen L, Adaway J, Keevil BG, Brabant G (2012) Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 97(2):408–415. doi: 10.1210/jc.2011-2134 CrossRefPubMedGoogle Scholar
- 30.Keefe CC, Goldman MM, Zhang K, Clarke N, Reitz RE, Welt CK (2014) Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS ONE 9(4):e93805. doi: 10.1371/journal.pone.0093805 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Grynberg M, Fanchin R, Dubost G, Colau JC, Bremont-Weil C, Frydman R, Ayoubi JM (2010) Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 20(4):553–558. doi: 10.1016/j.rbmo.2009.12.021 CrossRefPubMedGoogle Scholar
- 39.Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P et al (2009) Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 6(11):3193–3200. doi: 10.1111/j.1743-6109.2009.01380.x CrossRefPubMedGoogle Scholar
- 41.Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 15(5):972–978. doi: 10.1158/1055-9965.EPI-05-0848 CrossRefPubMedGoogle Scholar